5-fluorouracil,oxaliplatin,Irinotecan
Not Tagged
[]
norpact-1 trial results are truly mind-blowing. short-course neoadjuvant folfirinox did not improve survival and patients actually did worse! american society of clinical oncology (asco) 
Dr Rosario Ligresti is Chief of Gastroenterology at Hackensack University Medical Center. He is also Director of The Pancreas Center